ARTICLE | Product Development
With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond
Amgen’s Nuevolution acquisition is powering its push into targeted protein degradation and the wider world of induced proximity therapies
May 9, 2020 12:23 AM UTC
Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover multispecific therapies that trigger a broader set of biological functions.
Amgen’s rare M&A move was motivated by its Induced Proximity Platform, a unit the company launched about a year ago to develop compounds that bring two or more biological targets close enough to interact...